chevron_leftBack
As of 6 June 2026, NovoCure Ltd. has a market cap of $1.38B USD, ranking #8912 globally and #229 in the United Kingdom.
It ranks #755 in the Healthcare sector, and #150 in the Medical Devices industry.
Key Stats
Market Cap
$1.38BUSD
Enterprise Value
$1.18BUSD
Revenue (TTM)
$655.35MUSD
EBITDA (TTM)
-$135.16MUSD
Net Income (TTM)
-$136.23MUSD
EBITDA Margin
-21%
Profit Margin
-21%
PS Ratio
2.1
PB Ratio
3.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Frank Leonard
open_in_new
Employees
1,605
Founded
2000
IPO
02 Oct 2015
Website
novocure.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.6% | -8.4% | 8.8% | -5.2% | -11% | -35% |
News
Loading...
NVCR Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NVCR
NovoCure Ltd
ISIN: JE00BYSS4X48
Shares Out.:
Shares Outstanding:
115.821M1
Shares Float:
104.137M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
11.93 USD | |
|
NVCR
(NVCR/N)
NovoCure Ltd
ISIN: JE00BYSS4X48
|
322.39 MXN |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
LSE: SN
|
$13.27B
860%
9.88B GBP
|
21.8
|
|
LSE: CTEC
|
$5.7B
313%
4.25B GBP
|
34.0
|
|
NASDAQ: LIVN
|
$3.22B
133%
|
-
|
|
LSE: AMS
|
$725.43M
-47%
540.36M GBP
|
55.3
|
|
LSE: TSTL
|
$239.7M
-83%
178.54M GBP
|
22.9
|
|
LSE: EKF
|
$144.49M
-90%
107.63M GBP
|
53.2
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: TMO
|
$173.27B
12K%
|
25.8
|
|
NASDAQ: ISRG
|
$160.73B
12K%
|
56.7
|
|
NYSE: ABT
|
$159.07B
11K%
|
25.6
|
|
NYSE: DHR
|
$126.55B
9K%
|
34.7
|
|
NYSE: SYK
|
$120.69B
9K%
|
38.3
|
|
NYSE: MDT
|
$101.9B
7K%
|
22.2
|
chevron_leftBack